The Quantellect read.As of Nov 19, 2026, 4 active firms cover Milestone Pharmaceuticals Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $3.00 to $8.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $6.50 sits 1313% above the current $0.46. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.50
+1313.0% upside
Average target across 4 active firms as of Nov 19, 2026 vs $0.46 current
Highest Target$8.00
Average Target$6.50
Lowest Target$3.00
Detailed analyst forecasts for MIST
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate MIST a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MIST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.18 – $-0.13 · 3 analysts · -23% YoY
Next period, 3 analysts expect Milestone Pharmaceuticals Inc to earn $-0.15 a share (range $-0.18 – $-0.13), versus $-0.20 a year earlier. Full-year consensus is $-0.79, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$1.2M
Range $500.0K – $2.0M · 3 analysts · +414% YoY
Revenue is expected to reach $1.2M (range $500.0K – $2.0M), +414.2% year-over-year. Full-year consensus is $4.9M, rising to $12.6M next year.
Top analysts covering Milestone Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIST.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$10.00+2073.9% to target
Overall win rate
36%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$8.00+1639.1% to target
Overall win rate
38%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$7.00+1421.7% to target
Overall win rate
29%
+ Follow
#4
Mohit Bansal
Wells Fargo
Buy
$7.00+1421.7% to target
Coverage
—
+ Follow
#5
TF
Tiago Fauth
Raymond James
Buy
$5.00+987.0% to target
Coverage
—
+ Follow
MIST stock forecast FAQ
What is MIST's average 12-month price target?+
The 4 active firms with a live target average $6.50 for Milestone Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $3.00 low, as of Nov 19, 2026.
Is MIST stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MIST?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $3.00 (Cantor Fitzgerald). The average of all 4 active-firm targets is $6.50.
How many active Wall Street firms cover MIST?+
4 active firms have a recognized rating on Milestone Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MIST?+
Among analysts who currently cover MIST, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #308). Their current call is Buy with a $10.00 target.
What is Milestone Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.18 – $-0.13) across 3 analysts. Full-year EPS is projected at $-0.79, rising to $-0.61 the following year.
How much revenue is Milestone Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $1.2M (range $500.0K – $2.0M). Full-year revenue is projected at $4.9M, growing to $12.6M next year.
Have analysts been upgrading or downgrading MIST lately?+
As of Nov 19, 2026, 4 of 4 active firms rate MIST a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.